Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas.
Droog M, Nevedomskaya E, Kim Y, Severson T, Flach KD, Opdam M, Schuurman K, Gradowska P, Hauptmann M, Dackus G, Hollema H, Mourits M, Nederlof P, van Boven H, Linn SC, Wessels L, van Leeuwen FE, Zwart W. Droog M, et al. Among authors: opdam m. Cancer Res. 2016 Jul 1;76(13):3773-84. doi: 10.1158/0008-5472.CAN-14-1813. Epub 2016 May 6. Cancer Res. 2016. PMID: 27197147
CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment.
Beelen K, Opdam M, Severson TM, Koornstra RH, Vincent AD, Hauptmann M, van Schaik RH, Berns EM, Vermorken JB, van Diest PJ, Linn SC. Beelen K, et al. Among authors: opdam m. Breast Cancer Res Treat. 2013 Jun;139(3):649-55. doi: 10.1007/s10549-013-2568-0. Epub 2013 Jun 5. Breast Cancer Res Treat. 2013. PMID: 23736997 Free PMC article. Clinical Trial.
Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment.
Beelen K, Opdam M, Severson TM, Koornstra RH, Vincent AD, Wesseling J, Muris JJ, Berns EM, Vermorken JB, van Diest PJ, Linn SC. Beelen K, et al. Among authors: opdam m. Breast Cancer Res. 2014 Jan 21;16(1):R6. doi: 10.1186/bcr3598. Breast Cancer Res. 2014. PMID: 24447434 Free PMC article. Clinical Trial.
PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Beelen K, Opdam M, Severson TM, Koornstra RH, Vincent AD, Wesseling J, Muris JJ, Berns EM, Vermorken JB, van Diest PJ, Linn SC. Beelen K, et al. Among authors: opdam m. Breast Cancer Res. 2014 Jan 27;16(1):R13. doi: 10.1186/bcr3606. Breast Cancer Res. 2014. PMID: 24467828 Free PMC article. Clinical Trial.
4-protein signature predicting tamoxifen treatment outcome in recurrent breast cancer.
De Marchi T, Liu NQ, Stingl C, Timmermans MA, Smid M, Look MP, Tjoa M, Braakman RB, Opdam M, Linn SC, Sweep FC, Span PN, Kliffen M, Luider TM, Foekens JA, Martens JW, Umar A. De Marchi T, et al. Among authors: opdam m. Mol Oncol. 2016 Jan;10(1):24-39. doi: 10.1016/j.molonc.2015.07.004. Epub 2015 Aug 7. Mol Oncol. 2016. PMID: 26285647 Free PMC article.
SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer.
Zwart W, Flach KD, Rudraraju B, Abdel-Fatah TM, Gojis O, Canisius S, Moore D, Nevedomskaya E, Opdam M, Droog M, Hofland I, Chan S, Shaw J, Ellis IO, Coombes RC, Carroll JS, Ali S, Palmieri C. Zwart W, et al. Among authors: opdam m. Clin Cancer Res. 2016 Jan 15;22(2):479-91. doi: 10.1158/1078-0432.CCR-14-3277. Epub 2015 Sep 14. Clin Cancer Res. 2016. PMID: 26369632
50 results